



ABOUT CYTOMX

CytomX is a clinical-stage biopharmaceutical company focused on the goal of reinventing antibody therapeutics for the treatment of cancer through the development of a new generation of anti-cancer therapies called Probody™ therapeutics. Probody therapeutics are designed to exploit the unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity, limiting activity in healthy tissues to potentially solve the toxicity challenges associated with today's treatment options. We currently have four clinical-stage Probody programs.



The "masking" peptide is designed to limit the ability of Probody therapeutics to bind to healthy tissue—thereby helping to minimize toxicities.



In the tumor environment, protease enzymes are expected to cleave the substrate, removing the "mask" and activating the Probody therapeutic to bind to its target on cancer cells.

Our innovative pipeline focuses on a diverse array of next-generation therapies including Probody cancer immunotherapies, directed against clinically validated targets, such as PD-L1 and CTLA-4, and novel first-in-class Probody drug conjugates (PDCs) directed against difficult-to-drug targets such as CD166 and CD71. Additionally, the company has emerging applications for T cell engaging bispecific antibodies and chimeric antigen receptor (CAR) T cell therapies.

PROBODY THERAPEUTICS HAVE THE POTENTIAL TO:

- Overcome toxicity challenges associated with many current cancer treatments
- Enhance the efficacy and safety of combination regimens used to treat cancer
- Expand the universe of possible drug targets previously considered inaccessible to traditional antibody drug conjugates
- Offer new, more powerful treatment options—especially for patients underserved by current therapies

PRODUCT CANDIDATE	LEAD OPTIMIZATION	IND-ENABLING	PHASE 1/2	COMMERCIAL RIGHTS
CX-072	PD-L1 Probody Immunotherapy			CYTOMX THERAPEUTICS
CX-2009	CD166 Probody Drug Conjugate			CYTOMX THERAPEUTICS
BMS-986249	CTLA-4 Probody Immunotherapy			Bristol-Myers Squibb
CX-2029	CD71 Probody Drug Conjugate			abbvie, CYTOMX THERAPEUTICS
Probody Drug Conjugate	EpCAM PDC			immunogen
Probody T Cell Bispecifics	EGFR-CD3 Pb TCB			AMGEN, CYTOMX THERAPEUTICS
Additional PDCs, IO, TCBs				CYTOMX THERAPEUTICS

- Immunotherapies
- Probody drug conjugates
- T cell engaging bispecifics
- Multiple programs

CD166: activated leukocyte cell adhesion molecule
 CD71: transferrin receptor
 CTLA-4: cytotoxic T-lymphocyte-associated protein 4

IND: investigational new drug application
 IO: immunotherapy
 PDC: Probody drug conjugate

PD-1: programmed cell death protein 1
 PD-L1: programmed cell death ligand 1
 TCB: T cell engaging bispecific

LEAD CANDIDATES

CX-072 (PD-L1-TARGETING PROBODY THERAPEUTIC)

CX-072 is a wholly owned, PD-L1 targeting Probody therapeutic for the treatment of cancer currently being evaluated in a Phase 1/2 clinical trial as part of the PROCLAIM (**Pro**body **C**linical **A**ssesment **I**n **M**an) program. PROCLAIM enables clinical study sites and physicians to access CytomX's Probody therapeutics under one international umbrella. The first module within the PROCLAIM program is an open-label, dose-finding Phase 1/2 study evaluating CX-072 as monotherapy and in combination with Yervoy® (ipilimumab) or Zelboraf® (vemurafenib) in patients with certain cancers. CX-072 in combination with ipilimumab is in Phase 2 trials in relapsed refractory melanoma.

CytomX aims to achieve three goals as part of the PROCLAIM-072 clinical trial:	TOLERABILITY	Demonstrate that CX-072 is well tolerated in patients, and potentially improves safety, particularly in the combination setting.
	ANTI-CANCER ACTIVITY	Demonstrate initial evidence of CX-072's anti-cancer activity as monotherapy and in combination.
	TRANSLATIONAL PROGRAM AND PROBODY PLATFORM PROOF-OF-CONCEPT	Explore mechanistic aspects of Probody therapeutic activity in patients as observed in preclinical studies.

CX-2009 (CD166-DIRECTED PROBODY DRUG CONJUGATE)

CX-2009 is a wholly owned, first-in-class CD166-directed PDC for the treatment of cancer, currently being evaluated in a Phase 1/2 trial under the PROCLAIM program. The trial is evaluating CX-2009 as a monotherapy in patients with select advanced solid tumors. CX-2009 is the first PDC to target CD166, an antigen that is broadly and highly expressed in many types of cancers and has been previously considered "undruggable" given its expression on normal tissues. CX-2009 has been conjugated with DM4, a highly potent cytotoxic agent developed by and licensed from ImmunoGen.

BMS-986249 (CTLA-4-DIRECTED PROBODY THERAPEUTIC)

Bristol-Myers Squibb (BMS) is enrolling patients in a Phase 1/2 clinical trial to evaluate a CTLA-4-directed Probody therapeutic, BMS-986249, alone or in combination with Opdivo® (nivolumab) in solid cancers that are advanced or have spread. CTLA-4, a clinically validated inhibitory immune checkpoint protein, is the most advanced target collaboration which was first announced in 2014 and expanded in 2017.

CX-2029 (CD71-DIRECTED PROBODY DRUG CONJUGATE)

CytomX and AbbVie are co-developing CX-2029, a PDC directed against CD71, the transferrin receptor that is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues. CytomX is enrolling subjects in a Phase 1/2 clinical trial under the PROCLAIM program to evaluate CX-2029 as monotherapy in patients with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma.

ANALYSTS

Ticker Symbol:
NASDAQ:CTMX

Cantor Fitzgerald
Varun Kumar, Ph.D.

Citi
Mohit Bansal

Cowen & Company
Boris Peaker, Ph.D.

Goldman Sachs & Co. LLC
Terence Flynn, Ph.D.

H.C. Wainwright & Co.
Raghuram Selvaraju, Ph.D.

Jefferies LLC
Biren Amin

Mizuho Securities USA
Mara Goldstein

Nomura Instinet
Christopher N. Marai, Ph.D.

Piper Jaffray & Co
Joseph Cantanzaro, Ph.D.

Wedbush Securities
Robert Driscoll



KEY FACTS

151 Oyster Point Blvd
Suite 400
South San Francisco, CA
94080

Offices: 650.515.3185
Fax: 650.351.0353

www.cytomx.com

PARTNERSHIPS

CytomX actively seeks strategic partnerships to advance the next generation of highly targeted antibody therapies. These alliances allow us to broaden the application of our Probody platform and advance the most promising drug candidates to patients.

abbvie

In April 2016, CytomX entered into a strategic collaboration with AbbVie Inc. to co-develop and co-commercialize PDCs. Under the terms of the agreement, CytomX and AbbVie will co-develop a PDC against CD71, with CytomX leading pre-clinical and early clinical development. AbbVie will lead later development and commercialization, with global late-stage development costs shared between the two companies. AbbVie will lead global commercial activities with CytomX eligible to receive a profit share in the U.S. and tiered double-digit royalties on net product sales outside of the U.S. CytomX retains an option to co-promote in the U.S. AbbVie also receives exclusive worldwide rights to develop and commercialize PDCs against up to two additional, undisclosed oncology targets. In July 2019, AbbVie selected the first of two targets.

AMGEN

In 2017, CytomX entered into a strategic immuno-oncology collaboration with Amgen to co-develop T cell engaging bispecific therapeutics. The companies are co-developing a CytomX Probody T cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types, with CytomX leading early development. Amgen will lead later development and commercialization with global late-stage development costs shared between the two companies. CytomX is eligible to receive development, regulatory and commercial milestones for the EGFR program. Amgen will lead global commercial activities with CytomX able to opt into a profit share in the U.S. and receive tiered, double-digit royalties on net product sales outside of the U.S.

Amgen also receives exclusive worldwide rights to develop and commercialize up to three additional, undisclosed targets. Should Amgen ultimately pursue all of these targets, CytomX will be eligible to receive additional upfront and milestone payments and high single-digit to mid double-digit royalty payments on any resulting products. CytomX also receives the rights from Amgen to an undisclosed preclinical T cell engaging bispecific program. Amgen is eligible to receive milestones and royalty payments on any resulting products from this CytomX program.

 **Bristol-Myers Squibb**

In March 2017, CytomX and Bristol-Myers Squibb expanded their 2014 worldwide collaboration to discover, develop and commercialize novel therapies using CytomX's proprietary Probody platform. Bristol-Myers Squibb has progressed the most advanced target under the collaboration. BMS-986249, a CTLA-4 Probody therapeutic candidate, is currently in Phase 1 testing. Bristol-Myers Squibb is preparing to initiate the Phase 2 portion of BMS-986249, a CTLA-4 Probody therapeutic candidate.

IMMUNOGEN

In January 2014, CytomX entered into a multi-year, strategic collaboration with ImmunoGen, Inc. to develop PDCs for the treatment of cancer. Under the terms of the agreement, the companies will collaborate to develop PDCs against a defined number of targets. Each company retains full control of all of the products resulting from its target selection and is responsible for preclinical testing and development, clinical development, manufacturing and commercialization of its products.

We are advancing a deep oncology pipeline of Probody therapeutics by blazing our own trail and in partnership with some of the world's leading biopharmaceutical companies.



The breadth of the cancer targets and the cancer treatment approaches to which Probody technology may be applied has spurred value creating collaborations with industry leaders while CytomX retains full rights to its lead programs, CX-072 and CX-2009.